During the course of the treatment, leukemia was assessed as circulating human CD45 positive cells (Figure S5A): while there was persistence or gradual increase in the percentage of circulating human CD45 positive cells in the PBS-treated mice, this population remained undetectable in PR-104-treated mice. This evidence concerns the gene PTPRC and leukemia.